uMETHOD Health
uMETHOD Health is a Raleigh-based AI precision medicine company that develops personalized care plans for chronic diseases, primarily cognitive decline. Its RestoreU platform uses a proprietary Large Medical Model (IMHOTEP) to analyze EMR and lab data, distributed through major diagnostic laboratories to physicians nationwide.
- Company typePrivate
- Founded2013
- HeadquartersRaleigh, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What uMETHOD Health does
uMETHOD Health is a Raleigh, North Carolina-based healthcare technology company founded in 2013 that develops AI-powered precision medicine solutions for chronic diseases, with a primary focus on cognitive decline, mild cognitive impairment, and early-stage Alzheimer's disease. The company's flagship product, RestoreU METHOD, uses a proprietary Large Medical Model named IMHOTEP to process structured patient data — including electronic medical records, blood laboratory values, biomarkers, medications, comorbidities, and lifestyle factors — and assess more than 50 treatable risk factors to generate evidence-based, personalized care plans that combine FDA-approved medications, nutraceuticals, and lifestyle interventions. Two plan versions are produced (a detailed version for physicians and a simplified version for patients), with periodic retesting every six months to update recommendations. Adjacent products include ExtND METHOD for Alzheimer's prevention, the Immune Score assessment, and RenewU METHOD for depression, which is in development.
The platform's technology stack also incorporates fall risk assessment across 825 fall-risk-inducing drugs spanning 105 pharmacologic classes, automated compliance checklists for CMS Cognitive Assessment and Care Plan (CPT 99483) billing, and integration with cognitive assessment partners such as Linus Health. uMETHOD's go-to-market relies on distribution through reference laboratory partners — Quest Diagnostics (nationwide since May 2023), PathGroup, Sonora Quest Laboratories, and Tribal Diagnostics — supplemented by direct field sales via Business Development Executives targeting primary care, neurology, functional medicine, and C-suite buyers. The company earns revenue through SaaS-style platform licensing to lab partners and downstream transaction economics tied to the Medicare CPT 99483 reimbursement ($282 per qualifying encounter, billable twice annually per patient), with laboratory test services typically covered by Medicare.
uMETHOD maintains a Scientific Advisory Board including Dr. Marwan Sabbagh (Barrow Neurological Institute), Dr. P. Murali Doraiswamy (Duke), Dr. Richard Isaacson (Florida Atlantic), and Dr. Ken R. Pelletier (UCSF), and is led by CEO John Temperato (formerly of 9 Meters Biopharma, Melinta Therapeutics, and Salix Pharmaceuticals) alongside co-founders Vik Chandra (COO) and John Q. Walker, PhD (CTO). The company is privately held, with disclosed funding limited to small undisclosed rounds from The Pink Ceiling (2017) and Triangle Tweener Fund (2023 and Q3 2024 follow-on).
uMETHOD Health firmographics
Firmographics- Name
- uMETHOD Health
- Legal name
- uMETHOD
- Website
- https://umethod.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- uMETHOD Health is a Raleigh-based AI precision medicine company that develops personalized care plans for chronic diseases, primarily cognitive decline. Its RestoreU platform uses a proprietary Large Medical Model (IMHOTEP) to analyze EMR and lab data, distributed through major diagnostic laboratories to physicians nationwide.
- Ownership category
- akta.pro rank
uMETHOD Health industry classification
Industry- Product category
- Precision Medicine Software
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
- akta.pro secondary industry
- Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
Keywords
Where uMETHOD Health is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
uMETHOD Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- SaaS Platform Licensing through Lab Partners: uMETHOD provides its AI-powered RestoreU care planning platform through partnerships with diagnostic laboratories. Physicians order blood tests through lab partners, which trigger AI analysis and generate personalized care plans. Revenue is generated through these laboratory distribution partnerships.
- Medicare Cognitive Care Planning Reimbursement: The RestoreU care plan satisfies requirements for CMS Cognitive Care Planning Service (CPT code 99483). Medicare payment for this service is $282. Physicians can bill Medicare twice a year per patient if service elements criteria are met.
- Laboratory Test Services: Blood tests ordered by physicians through reference lab partners (Quest Diagnostics, PathGroup, Sonora Quest, Tribal Diagnostics) are typically covered by Medicare. These lab panels feed the care plan generation process.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Multi-year contract | Cognitive Care Planning Service (CPT 99483) |
| Subscription | Annual | RestoreU Dementia Panel via Lab Partners |
Go-to-market motion1 record
Distribution channels6 records
Marketing channels8 records
uMETHOD Health product offering
Product offeringCore offering
uMETHOD Health develops and licenses the AI-powered RestoreU platform, which applies a proprietary Large Medical Model (IMHOTEP) to patient EMR data, lab values, biomarkers, medications, and medical history to generate personalized, multi-domain care plans for chronic diseases such as cognitive decline and Alzheimer's. The platform is delivered to physicians through reference laboratory partners (Quest Diagnostics, PathGroup, Sonora Quest, Tribal Diagnostics), enabling blood test orders to trigger AI-generated treatment plans that incorporate FDA-approved medications, nutraceuticals, and lifestyle interventions, while supporting Medicare Cognitive Assessment and Care Plan (CPT 99483) reimbursement.
Product overview
uMETHOD Health offers a platform of AI-powered precision medicine solutions for chronic diseases with multiple underlying causes. The core offerings include RestoreU METHOD for cognitive decline/Alzheimer's care, ExtND METHOD for Alzheimer's prevention, RenewU METHOD for depression (in development), and Immune Score for immune system assessment. The RestoreU platform is the primary product, using a proprietary Large Medical Model (IMHOTEP) to analyze patient data from lab results, medical history, and medications to generate personalized care plans addressing 50+ risk factors. Care plans include FDA-approved medications, nutraceuticals, and lifestyle recommendations, with patient coaching support. The platform integrates with major diagnostic laboratories (Quest Diagnostics, PathGroup, Sonora Quest, Tribal Diagnostics) for lab data and Health Gorilla for health information exchange.
Differentiator
Problem solved
Functional benefit
Brands
- RestoreU METHOD: AI-enabled precision care platform for memory loss, mild cognitive impairment, and early dementia that creates personalized care plans based on patient EMR data and lab values
- RenewU METHOD
- Immune Score
Products and services
- RestoreU METHOD AI-powered precision medicine platform that analyzes patient EMR data, lab values, biomarkers, medications, and medical history to create personalized care plans for patients with mild cognitive impairment, mild dementia, or mild Alzheimer's disease. Care plans include FDA-approved medications, nutraceuticals, and lifestyle recommendations, supported by personal coaches, and are refreshed every six months.
- ExtND METHOD Prevention-focused precision medicine methodology that delivers personalized prevention plans addressing dozens of biological mechanisms and hundreds of interventions for individuals at risk of Alzheimer's disease and cognitive decline.
- Immune Score Immune system health assessment tool that evaluates biomarkers, medications, and comorbidities to produce an Immune Score from 1 to 100, with a report identifying contributing factors to immune compromise and tracking changes over time.
- RestoreU Patient Portal Web-based portal for patients to access their uMETHOD account, view personalized care plans, and manage their cognitive care journey, including login, password recovery, and new patient registration functionality.
Quantifiable outcome
- 76% of overall population improved or held steady on CNS-VS composite memory scores (from 40.4% to 55.9%)
- +3 more outcomes
Companies that use uMETHOD Health
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
uMETHOD Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability6 records
Feature6 records
uMETHOD Health partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Linus HealthcoreCollaboration to create a more efficient and effective approach to brain health. The integration combines Linus Health's advanced cognitive assessments with uMETHOD's personalized care planning, enabling clinicians with comprehensive cognitive assessments and streamlined workflows from assessment to care planning.
- Tribal DiagnosticsminorNative American-owned high-complexity diagnostics laboratory offering RestoreU Dementia Panel throughout Texas and Oklahoma, focused on serving tribal and non-tribal physicians and patients.
- Quest DiagnosticscoreQuest Diagnostics, a Fortune 500 diagnostic information services company, offers the RestoreU Dementia Panel nationwide through its testing portfolio. The partnership provides AI-powered risk assessment and personalized care planning for cognitive decline, complementing Quest's 400+ neurology tests including AD-Detect Amyloid Beta 42/40 Ratio.
- PathGroupcorePathGroup, one of the largest independent laboratories in the US, partnered with uMETHOD to offer AI-based care planning solution paired with comprehensive testing for mild cognitive impairment and early-stage Alzheimer's patients.
- GetlabsminorAt-home diagnostics provider supplying mobile phlebotomies for uMETHOD patients in Arizona, making blood tests accessible for patients with cognitive decline.
- Sonora Quest LaboratoriescoreArizona's leading diagnostic laboratory partnered with uMETHOD to provide RestoreU METHOD for patients experiencing memory loss, including lab tests and individualized care plans to assess and minimize risk of developing Alzheimer's.
- Dr. Marwan SabbaghcoreNeurologist and geriatric neurologist at Barrow Neurological Institute serving on uMETHOD's Scientific Advisory Board. Actively promotes RestoreU in clinical practice and presentations.
- Dr. P. Murali DoraiswamycoreDuke University faculty member serving on uMETHOD's Scientific Advisory Board.
- Dr. Richard IsaacsoncoreFlorida Atlantic University faculty member serving on uMETHOD's Scientific Advisory Board.
- Dr. Ken R. PelletiercoreUniversity of California, San Francisco faculty member serving on uMETHOD's Scientific Advisory Board.
- Dr. Robert KachkocoreBoard member of American Association of Naturopathic Physicians serving on uMETHOD's Scientific Advisory Board.
Scale indicators5 records
Recent moves6 records
Expansion highlights7 records
uMETHOD Health competitors and assessment
Company assessmentOthers
- Quest Diagnostics: Quest Diagnostics is uMETHOD's largest distribution partner, offering RestoreU Dementia Panel nationwide as part of its 400+ neurology test menu. Not a competitor — included as an ecosystem participant whose channel decisions materially shape uMETHOD's growth trajectory.
- Medisafe: Medisafe is a medication adherence and personalized care management platform for chronic disease patients. While not focused on cognition, it overlaps with uMETHOD on personalized care plan delivery and medication adherence for chronic-condition populations.
Emerging players
- Akili Interactive (Virtual Therapeutics): Akili (relaunched as Virtual Therapeutics) is a digital therapeutics company that had FDA-cleared prescription digital therapeutics for cognition, including EndeavorRx. Adjacent to uMETHOD on digital, FDA-cleared cognitive interventions for brain health conditions.
- C2N Diagnostics: C2N Diagnostics offers the PrecivityAD blood-based Alzheimer's diagnostic, which Quest Diagnostics distributes as AD-Detect. C2N overlaps with uMETHOD on the lab-distributed Alzheimer's diagnostic pathway feeding into cognitive care workflows, but focuses on the biomarker test rather than ongoing care plan generation.
Direct peers
- Neurotrack: Neurotrack develops digital cognitive health tools, including cognitive assessments and brain health programs aimed at early detection of impairment. Direct overlap with RestoreU on screening, risk assessment, and consumer/physician-facing cognitive health.
- Cogstate: Cogstate provides computerized cognitive testing for clinical trials, healthcare, and brain health. Overlaps with uMETHOD on computerized cognitive assessment delivery and physician-facing cognitive care, though more weighted toward clinical trials.
- Linus Health: Linus Health is a digital health company enabling early detection of cognitive impairment and Alzheimer's via AI-driven cognitive assessments, and is an explicit partner of uMETHOD for combined assessment-plus-care-planning workflows. Most directly comparable peer given overlapping product, target clinicians, and patient population.
- BrainCheck: BrainCheck offers a digital cognitive assessment and care planning platform used by physicians to detect and manage cognitive impairment. Directly comparable to RestoreU on cognitive screening, physician workflow, and clinical decision support.
- Cambridge Cognition: Cambridge Cognition offers digital cognitive assessment tools, including CANTAB, used by clinicians and researchers to detect and monitor cognitive decline. Comparable to uMETHOD on digital cognitive endpoints and clinician workflows in memory care.
- Altoida: Altoida is a digital health company using AI-driven digital biomarkers to predict and assess cognitive impairment and Alzheimer's risk, with FDA Breakthrough Device designation. Closely comparable to uMETHOD on AI-driven cognitive biomarker analysis for early impairment detection.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights8 records
Customer concentration
uMETHOD Health social profiles
Digital presenceuMETHOD Health compliance and trust
Trust signalCompliance2 records
uMETHOD Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
uMETHOD Health leadership team
Management profileNumber of profiles
Profiles7 records
uMETHOD Health funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
uMETHOD Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about uMETHOD Health
What does uMETHOD Health do?
uMETHOD Health develops and licenses the AI-powered RestoreU platform, which applies a proprietary Large Medical Model (IMHOTEP) to patient EMR data, lab values, biomarkers, medications, and medical history to generate personalized, multi-domain care plans for chronic diseases such as cognitive decline and Alzheimer's. The platform is delivered to physicians through reference laboratory partners (Quest Diagnostics, PathGroup, Sonora Quest, Tribal Diagnostics), enabling blood test orders to trigger AI-generated treatment plans that incorporate FDA-approved medications, nutraceuticals, and lifestyle interventions, while supporting Medicare Cognitive Assessment and Care Plan (CPT 99483) reimbursement.
Is uMETHOD Health a public or private company?
uMETHOD Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was uMETHOD Health founded?
uMETHOD Health was founded in 2013. It employs 11 to 50 people.
Where is uMETHOD Health based?
uMETHOD Health is headquartered in Raleigh, United States, in the North America region.
How does uMETHOD Health make money?
Three revenue lines are on record. SaaS Platform Licensing through Lab Partners are the primary driver. The others are medicare Cognitive Care Planning Reimbursement and laboratory Test Services.
Who are uMETHOD Health's main competitors?
Others on record are Quest Diagnostics and Medisafe. Emerging players are Akili Interactive (Virtual Therapeutics) and C2N Diagnostics. Direct peers are Neurotrack, Cogstate, Linus Health, BrainCheck, Cambridge Cognition and Altoida.
Does uMETHOD Health have an API?
No public API is recorded for uMETHOD Health.
What industry is uMETHOD Health in?
uMETHOD Health's product category is Precision Medicine Software. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs). Its SIC code is 8000.